Advertisement

Search For Environmental Or Endogenous Neurotoxins Related To MPTP

  • S. P. Markey
  • H. Ikeda
  • S.-C. Yang
  • C. J. Markey
  • A. M. Marini
  • J. N. Johannessen
Chapter

Abstract

The cause of Parkinson’s disease remains unknown despite clinical investigations of infectious, genetic, or other contributory etiologic factors (1). Neurotoxins have been considered as causative agents in past clinical investigations due particularly to the observations of parkinsonian symptomatology caused by manganese, 6-hydroxydopamine, neuroleptics, carbon monoxide, and carbon disulfide (2). The clinical responses to each of these neurotoxins differed distinctly from Parkinson’s disease, and thus when MPTP-induced neurotoxicity was first observed (3,4), it generated considerable interest because it closely paralleled the idiopathic disease condition in nearly every aspect. MPTP-induced parkinsonism in non-human primates differs from the idiopathic disease in humans only in its rapid course, the apparent lack of progression following the toxic insult, the absence of the neuropathological hallmark Lewy bodies, and the limited involvement of neurons other than the nigro-striatal in MPTP-affected animals (5). These observations have reawakened interest in a neurotoxic etiology of Parkinson’s disease and have enabled us to define new stategies and tools for these investigations.

Keywords

Cerebellar Granule Cell Brain Extract Fluorescein Diacetate Cation Resin MPTP Toxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Duvoisin, R.C.: The cause of Parkinson’s disease. In: Movement Disorders, Chap. 2, Marsden, C.D., Fahn, S. (Eds.), Butterworth Scientific, London, pp. 8–24, 1987.Google Scholar
  2. Schwab, R.C., England, A.C., Jr.: Parkinson Syndromes due to various specific causes. In: Handbook Clin. Neurology, Chap. 9, Vinken, P.J., Bruyn, G.W. (Eds.), North Holland, pp. 227–247, 1968.Google Scholar
  3. Davis, G.C., Williams, A.C., Markey, S.P., Ebert, M.H., Caine, E.D., Reichert, C.M., Kopin, I.J.: Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Research 1:249–254, 1979.PubMedCrossRefGoogle Scholar
  4. Langston, J.W., Ballard, P., Tetrud, J.W., Irwin, I.: Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980, 1983.PubMedCrossRefGoogle Scholar
  5. Kopin, I.J., Markey, S.P.: MPTP toxicity: Implications for research in Parkinson’s disease. Ann. Review Neurosci. 11:81–96, 1988.CrossRefGoogle Scholar
  6. Markey, S.P, Markey, C.J., Savitt, J.M., Bacon, J.P., Johannessen, J.N.: Search for environmental neurotoxins related to MPTP. Preparation of antibodies to MPTP and MPP+. In: MPTP — A Neurotoxin Producing A Parkinsonian Syndrome. Chap. 44, Markey, S.P, Castagnoli, N., Jr., Trevor, A.J., Kopin, I.J. (Eds.), Academic Press, Orlando, FL, pp. 487–493, 1986.Google Scholar
  7. Johannessen, J.N., Savitt, J.M., Markey, C.J., Bacon, J.P., Weisz, A., Hanselman, D.S., Markey, S.P.: The development of amine substituted analogues of MPTP as unique tools for the study of MPTP toxicity and Parkinson’s disease. Life Sci. 40:697–707, 1987.PubMedCrossRefGoogle Scholar
  8. Yang, S.C., Johannessen, J.N., Markey, S.P: Metabolism of 14C-[phenyl]-MPTP in mouse and monkey implicates MPP +, and not bound metabolites, as the operative neurotoxin. Submitted for publication.Google Scholar
  9. Carr, R.I., Mansour, M., Sadi, D., James, H., Jones, J. V.: A substrate amplification system for enzyme-linked immunoassays. Demonstration of its general applicability to ELISA systems for detecting antibodies and immune complexes. J. Immun. Methods 98: 201–208, 1987.CrossRefGoogle Scholar
  10. Gallo, V., Ciotti, M.T., Coletti, A., Aloisi, F., Levi, G.: Selective release of glutamate from cerebellar granule cells differentiating in culture. Proc. Natl. Acad. Sci. USA 79:7919–7923, 1982.PubMedCrossRefGoogle Scholar
  11. Novelli, A., Reilly, J. A., Lysko, PG., Henneberry, R.C.: Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. (in press) 1988.Google Scholar
  12. Niewola, Z., Walsh, S.T., Davies, G.E.: Enzyme linked immunosorbent asssay (ELISA) for paraquat. Int. J. Immunopharmacol. 5:211–218, 1983.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • S. P. Markey
    • 1
  • H. Ikeda
    • 1
  • S.-C. Yang
    • 1
  • C. J. Markey
    • 1
  • A. M. Marini
    • 2
  • J. N. Johannessen
    • 1
  1. 1.Laboratory of Clinical Science, National Institute of Mental HealthBethesdaUSA
  2. 2.Clinical Neuroscience BranchNational Institute of Neurological and Communicative Disorders and StrokeBethesdaUSA

Personalised recommendations